Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Transfusion Clear all
Completed Phase 2 Interventional Results available

Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty

NCT01370460
View directory record Official record
Conditions
Acute Blood Loss Anemia, Osteoarthritis, Knee
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jun 9, 2026, 11:37 PM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jun 9, 2026, 11:37 PM EDT
Completed No phase listed Observational

The Utility of the Validated Intraoperative Bleeding Scale in Spine Surgery

NCT05258487
View directory record Official record
Conditions
Intraoperative Blood Loss, Thoracolumbar Spine Surgery
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Jun 9, 2026, 11:37 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

NCT03263091
View directory record Official record
Conditions
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
30
States / cities
Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jun 9, 2026, 11:37 PM EDT
Withdrawn Not applicable Interventional

Blood Conservation in Cardiac Surgery

NCT01463345
View directory record Official record
Conditions
Transfusion Reactions, Post Cardiac Surgery
Interventions
Blood transfusion
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Jun 9, 2026, 11:37 PM EDT
Withdrawn Phase 1 Interventional

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Jun 9, 2026, 11:37 PM EDT
Recruiting No phase listed Observational

Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

NCT06944067
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

Red Cell Storage Duration and Outcomes in Cardiac Surgery

NCT00458783
View directory record Official record
Conditions
Blood Transfusion, Cardiac Surgery
Interventions
Prolonged RBC storage, Short RBC storage
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3,942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional

Optimized Erythropoietin (EPO) Treatment

NCT02075970
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Epoetin Alpha, Biotinylated Red Blood Cells
Drug
Lead sponsor
John A Widness
Other
Eligibility
Up to 2 Days
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

NCT04173494
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib, Placebo to match danazol, Danazol, Placebo to match momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jun 9, 2026, 11:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

NCT01499888
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus
Procedure · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
16 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jun 9, 2026, 11:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

NCT03999229
View directory record Official record
Conditions
Transfusion Related Complication
Interventions
SNO, Normal Saline, Red Blood Cell
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 35 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jun 9, 2026, 11:37 PM EDT
Terminated Not applicable Interventional Results available

TXA Study in Major Burn Surgery

NCT02753816
View directory record Official record
Conditions
Tranexamic Acid, Burn, Major Surgery
Interventions
Tranexamic Acid, Placebo Comparator
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Jun 9, 2026, 11:37 PM EDT
Recruiting Not applicable Interventional

HEME Home Transfusion Program

NCT06487247
View directory record Official record
Conditions
Leukemia, Myeloma, Myelodysplastic Syndromes, Hematologic Malignancy, Hematologic Diseases, Lymphoma
Interventions
HEME-Hospice Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Not applicable Interventional

The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?

NCT02606058
View directory record Official record
Conditions
Preterm Birth
Interventions
Deferred cord clamping
Procedure
Lead sponsor
University of Sydney
Other
Eligibility
Female only
Enrollment
1,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Houston, Texas • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Results available

Early Whole Blood in Patients Requiring Transfusion After Major Trauma

NCT01227005
View directory record Official record
Conditions
Trauma/Injury Problem
Interventions
Transfusion of blood products
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jun 9, 2026, 11:37 PM EDT
Not listed Phase 1 Interventional

Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.

NCT03591302
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total Lymphoid irradiation
Biological · Radiation
Lead sponsor
Stephan Busque
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jun 9, 2026, 11:37 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT01419704
View directory record Official record
Conditions
Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies, Thalassemia, Diamond-Blackfan Anemia, Bone Marrow Failure Syndromes, Alpha-Thalassemia, Beta-Thalassemia
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jun 9, 2026, 11:37 PM EDT
Terminated Phase 1 Interventional

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

NCT02295501
View directory record Official record
Conditions
Acute Ebola Virus Disease
Interventions
INTERCEPT Plasma
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

NCT01178281
View directory record Official record
Conditions
Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions
Pomalidomide 0.5 mg, Placebo, Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.

NCT02754999
View directory record Official record
Conditions
Acute Anemia
Interventions
SANGUINATE™
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Prescott, Arizona • Baldwin Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Results available

Effects of Microplegia on Transfusion Rates After Cardiac Surgery

NCT05076604
View directory record Official record
Conditions
Aortic Valve Disease, Mitral Valve Disease
Interventions
Cardioplegia Solution, Microplegic Solution No. 1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 9, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available

Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)

NCT01671111
View directory record Official record
Conditions
Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions
SSP-004184AQ
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Oakland, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Jun 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

NCT01545232
View directory record Official record
Conditions
Trauma
Interventions
1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jun 9, 2026, 11:37 PM EDT